Scarica l'app Stockscreener
57.46
0.23%
0.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$57.27
Aprire:
$56.96
Volume 24 ore:
108.12K
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.24B
Reddito:
$486.82M
Utile/perdita netta:
$18.78M
Rapporto P/E:
70.07
EPS:
0.82
Flusso di cassa netto:
$100.45M
1 W Prestazione:
-4.32%
1M Prestazione:
-16.05%
6M Prestazione:
+0.86%
1 anno Prestazione:
-4.90%
Intervallo 1D:
$56.71
$57.79
Intervallo di 1 settimana:
$56.71
$61.23
Portata 52W:
$52.50
$77.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Nome
Ani Pharmaceuticals Inc
Settore
Telefono
(218) 634-3500
Indirizzo
210 MAIN STREET WEST, BAUDETTE, MN
Confronta ANIP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
57.42 | 1.29B | 486.82M | 18.78M | 100.45M | 0.82 |
|
HLN
Haleon Plc Adr
|
11.15 | 48.05B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
162.29 | 71.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8091 | 3.20M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.54 | 43.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.91 | 19.35B | 16.54B | -1.64B | 749.00M | -1.45 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-14 | Iniziato | Jefferies | Buy |
| 2025-03-12 | Iniziato | JP Morgan | Overweight |
| 2024-12-11 | Iniziato | Leerink Partners | Outperform |
| 2024-10-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-15 | Iniziato | CapitalOne | Overweight |
| 2023-08-22 | Reiterato | H.C. Wainwright | Buy |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-02 | Iniziato | Truist | Buy |
| 2020-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-05-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Reiterato | Canaccord Genuity | Buy |
| 2017-07-31 | Iniziato | Canaccord Genuity | Buy |
| 2017-02-22 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Iniziato | Raymond James | Strong Buy |
| 2016-05-24 | Downgrade | Standpoint Research | Buy → Hold |
| 2015-11-13 | Iniziato | Standpoint Research | Buy |
| 2015-09-28 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
| 2015-08-04 | Reiterato | ROTH Capital | Neutral |
| 2015-07-31 | Reiterato | Oppenheimer | Outperform |
| 2015-07-15 | Reiterato | ROTH Capital | Neutral |
| 2015-06-23 | Reiterato | Oppenheimer | Outperform |
| 2015-05-18 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Reiterato | Oppenheimer | Outperform |
| 2015-04-10 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Reiterato | ROTH Capital | Buy |
| 2015-02-18 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie
ANI Pharmaceuticals Approves Key Proposals at Annual Meeting - TipRanks
ANI Pharmaceuticals Expands Stock Plans and Shares - Investing.com
Have Insiders Sold ANI Pharmaceuticals Shares Recently? - simplywall.st
ANI Pharmaceuticals Launches Phase 4 Trial of Cortrophin Gel for Acute Gout Flares - marketscreener.com
ANI Pharmaceuticals (ANIP) Starts Phase 4 Trial for Acute Gout Treatment | ANIP Stock News - GuruFocus
ANI Pharmaceuticals Announces Initiation of Phase 4 - GlobeNewswire
ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth - insights.citeline.com
ANI Pharmaceuticals To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation - simplywall.st
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Voyager Therapeutics (VYGR) and Privia Health Group (PRVA) - The Globe and Mail
ANI Pharmaceuticals (ANIP) Price Target Raised by Raymond James - GuruFocus
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ - GlobeNewswire
ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | - GuruFocus
ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | ANIP Stock News - GuruFocus
ANI Pharmaceuticals raises 2025 revenue guidance to $768M-$793M with 25%-29% growth - MSN
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges - Investing.com UK
ANI Pharmaceuticals Inc (ANIP) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insight - GuruFocus
ANI Pharmaceuticals Reports Record Q1 2025 Results - TipRanks
Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com South Africa
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact - AOL.com
ANI: Q1 Earnings Snapshot - The Washington Post
Transcript : ANI Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ANI Pharmaceuticals Boosts Q1 Revenue with Strong Performance | - GuruFocus
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
ANI Pharmaceuticals, Inc. Q1 Profit Decreases, But Beats Estimates - Nasdaq
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance - The Manila Times
ANI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ANI Pharmaceuticals (NASDAQ:ANIP) Reports Strong Q1, Full-Year Outlook Slightly Exceeds Expectations - FinancialContent
(ANIP) ANI Pharmaceuticals Expects Fiscal Year 2025 Revenue Range $768M$793M - marketscreener.com
(ANIP) ANI Pharmaceuticals Forecasts Fiscal Year 2025 Adjusted EPS Range $6.27$6.62 - marketscreener.com
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? - MSN
ANI Pharmaceuticals Files Proxy for 2025 Meeting - TipRanks
ANI Pharmaceuticals Set to Announce Earnings Results: Key ExpectationsNews and Statistics - IndexBox
Earnings To Watch: ANI Pharmaceuticals (ANIP) Reports Q1 Results Tomorrow - Yahoo Finance
ANI Pharmaceuticals: A Short-Term Buying Opportunity (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance - ADVFN
ANI Pharmaceuticals (ANIP) Highlights Promising Cortrophin Gel P - GuruFocus
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model - GlobeNewswire
Breakthrough: ANI's Cortrophin Gel Achieves Dose-Dependent Success in Autoimmune Eye Disease Trial - Stock Titan
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Scotiabank Announces Redemption of US $1,250 million 4.900% Fixed Rate Resetting Perpetual Subordinated Additional Tier 1 Capital Notes - The Globe and Mail
Ani Pharmaceuticals Inc Azioni (ANIP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.82%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):